Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.
Humans
Aged
Carcinoma, Hepatocellular
/ epidemiology
Antiviral Agents
/ therapeutic use
Liver Neoplasms
/ etiology
Retrospective Studies
Angiopoietin-2
/ therapeutic use
Hepatitis C, Chronic
/ complications
Neoplasm Recurrence, Local
/ epidemiology
Hepatitis C
/ complications
Hepacivirus
/ genetics
Risk Factors
Liver Cirrhosis
/ drug therapy
angiopoietin-2
direct-acting antiviral
hepatitis C virus
hepatocellular carcinoma
recurrence
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
07 01 2023
07 01 2023
Historique:
received:
10
12
2022
revised:
03
01
2023
accepted:
05
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Progressive liver fibrosis after anti-HCV treatment is a risk factor for HCC. Angiopoietin-2 (Ang2) is associated with non-regression of liver fibrosis after direct-acting antiviral (DAA). This study evaluated the predictive value of serum Ang2 levels for HCC occurrence or recurrence after DAA administration. In this retrospective study, 310 HCV-infected patients treated with DAAs in 2014-2020 were screened and evaluated for HCC occurrence or recurrence every three-six months. Multivariate Cox regression analysis revealed that age ≥ 75 years (HR: 2.92, 95% CI: 1.34-6.33;
Identifiants
pubmed: 36680221
pii: v15010181
doi: 10.3390/v15010181
pmc: PMC9862289
pii:
doi:
Substances chimiques
Antiviral Agents
0
Angiopoietin-2
0
Banques de données
UMIN-CTR
['UMIN000031091']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Gastroenterol. 2021 Jan;56(1):67-77
pubmed: 33001338
J Gastroenterol. 2019 Jul;54(7):641-649
pubmed: 30778716
J Gastroenterol Hepatol. 2021 May;36(5):1152-1158
pubmed: 32667068
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):724-735
pubmed: 35576953
Hepatol Res. 2020 Jun;50(6):671-681
pubmed: 32020702
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1298-1303
pubmed: 29358379
Hepatology. 2019 Mar;69(3):1087-1104
pubmed: 30259536
J Gastroenterol. 2018 May;53(5):591-605
pubmed: 29299684
PLoS One. 2013 Aug 05;8(8):e70459
pubmed: 23940579
Hepatology. 2018 Sep;68(3):1010-1024
pubmed: 29604220
Hepatol Res. 2015 Jan;45(2):238-46
pubmed: 24655233
PLoS One. 2021 Mar 1;16(3):e0247728
pubmed: 33647018
Aliment Pharmacol Ther. 2018 Jan;47(1):104-113
pubmed: 29035002
Hepatol Res. 2022 Jul;52(7):603-613
pubmed: 35352857
Ann Intern Med. 2000 Apr 4;132(7):517-24
pubmed: 10744587
Ophthalmology. 2019 Aug;126(8):1155-1170
pubmed: 30905643
Liver Int. 2015 Apr;35(4):1383-92
pubmed: 24612347
Hepatology. 2018 May;67(5):1683-1694
pubmed: 28960366
Hepatology. 2019 Feb;69(2):729-741
pubmed: 30141205
N Engl J Med. 2015 Aug 20;373(8):705-13
pubmed: 26196665
Sci Rep. 2022 Jan 27;12(1):1449
pubmed: 35087141
J Hepatol. 2018 Sep;69(3):603-607
pubmed: 29886154
J Hepatol. 2017 Sep 05;:
pubmed: 28887168
J Hepatol. 2017 Nov;67(5):933-939
pubmed: 28627363
Gastroenterology. 2018 Oct;155(4):1120-1127.e4
pubmed: 29958855
Sci Rep. 2021 Apr 28;11(1):9207
pubmed: 33911145
J Gastroenterol. 2019 Jan;54(1):78-86
pubmed: 30019127
J Gastroenterol. 2017 Oct;52(10):1122-1129
pubmed: 28315983
Hepatol Res. 2019 Feb;49(2):136-146
pubmed: 30335208
Hepatol Res. 2020 Jun;50(6):715-725
pubmed: 32202371
Nat Rev Drug Discov. 2017 Sep;16(9):635-661
pubmed: 28529319
Clin Infect Dis. 2018 Sep 14;67(7):1010-1017
pubmed: 29566246
JGH Open. 2020 Apr 11;4(5):880-888
pubmed: 33102759
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30381417
J Gastroenterol. 2016 Jul;51(7):733-40
pubmed: 26768604
Nutrients. 2021 Jul 14;13(7):
pubmed: 34371925
J Cell Physiol. 2008 Feb;214(2):491-503
pubmed: 17960565
J Gastroenterol. 2018 Jan;53(1):119-128
pubmed: 28560477